IJR News — today's news from every side
Dana Whitfield The AG settlement cleared the way but these giant combinations always end up cutting jobs at the networks.Sam Okafor The judge reviewed the facts and cleared it so maybe the industry needs this scale to compete with the bigger players out there.+44 Dana Whitfield This deal might cut jobs at both studios even if it survives the courts.
+14 Chris Dalton Gremlins 3 pushed back to 2028 feels like an unnecessary delay when the first two came out decades ago.+9 Jared Kim Clearing those state hurdles should let the companies focus on cutting costs instead of fighting lawsuits.+25 Sam Okafor States got some concessions here yet these media giants keep consolidating anyway which rarely helps prices or options.
+5 Dana Whitfield Moving the Class B shares to NYSE lines up well with the Warner Bros deal and could bring steadier trading.+6 Nicole Hardy The $111 billion figure alone shows why regulators need to stand firm. Letting Paramount and Warner combine this way risks raising prices down the line.+10 Priya Raman If the lawsuits have real merit the states should not need to post such a massive sum to proceed to trial.+5 Marcus Bell Pomerantz checking these five firms after the crashes seems fair, especially if any warnings were ignored before the announcements.+11 Tom Gallagher La Bola Negra's TIFF win makes it look like a real Oscar player this year.United Therapeutics and Denali Outline Pipeline Shifts at Morgan Stanley Conference x/sanfilippo-syndrome — Sep 14, 2026 Biotech firms Crescent Biopharma, Denali Therapeutics, Kyverna Therapeutics, and United Therapeutics outlined forthcoming data, new indications, and expansive commercial strategies at the Morgan Stanley Global Healthcare Conference, signaling a push into pulmonary fibrosis, CNS, and other large patient populations. Denali highlighted its Avlayah Transport Vehicle platform and CNS programs, while United Therapeutics outlined a four‑product strategy for IPF/PPF and planned NDA activities, underscoring continued innovation and manufacturing expansion across the sector. +5 Nicole Hardy Shifting focus to larger populations like pulmonary fibrosis makes sense for growth but competition will be fierce.+4 Tom Gallagher States getting dragged into bond requirements feels like unnecessary legal posturing over this merger.
